Format

Send to

Choose Destination
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26826. Epub 2017 Sep 19.

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice.

Author information

1
Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
2
Columbia University College of Physicians and Surgeons, New York, New York.
3
Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

Medical marijuana (MM) has become increasingly legal at the state level and accessible to children with serious illness. Pediatric patients with cancer may be particularly receptive to MM, given purported benefits in managing cancer-related symptoms. In this review, we examine the evidence for MM as a supportive care agent in pediatric oncology. We describe the current legal status of MM, mechanism of action, common formulations, and potential benefits versus risks for pediatric oncology patients. We offer suggestions for how providers might approach MM requests. Throughout, we comment on avenues for future investigation on this growing trend in supportive care.

KEYWORDS:

medical marijuana; pediatric oncology; supportive care

PMID:
28926679
DOI:
10.1002/pbc.26826
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center